BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kok PS, Cho D, Yoon WH, Ritchie G, Marschner I, Lord S, Friedlander M, Simes J, Lee CK. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e2011809. [PMID: 32897371 DOI: 10.1001/jamanetworkopen.2020.11809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Bergamino Sirvén M, Pernas S, Cheang MCU. Lights and Shadows in Immuno-Oncology Drug Development. Cancers (Basel) 2021;13:691. [PMID: 33572060 DOI: 10.3390/cancers13040691] [Reference Citation Analysis]
2 Goring S, Varol N, Waser N, Popoff E, Lozano-Ortega G, Lee A, Yuan Y, Eccles L, Tran P, Penrod JR. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis. Lung Cancer 2022;170:122-32. [PMID: 35767923 DOI: 10.1016/j.lungcan.2022.06.009] [Reference Citation Analysis]
3 Palmieri G, Rozzo CM, Colombino M, Casula M, Sini MC, Manca A, Pisano M, Doneddu V, Paliogiannis P, Cossu A. Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy? Front Oncol 2021;11:666624. [PMID: 34026645 DOI: 10.3389/fonc.2021.666624] [Reference Citation Analysis]
4 Xu H, Cao D, Zheng Y, Zhou D, Chen X, Lei J, Ge W, Xu X. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol 2021;100:108135. [PMID: 34530205 DOI: 10.1016/j.intimp.2021.108135] [Reference Citation Analysis]
5 Shameer K, Zhang Y, Prokop A, Nampally S, N IKA, Weatherall J, Iacona RB, Khan FM. OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials. JCO Clin Cancer Inform 2022;6:e2100173. [PMID: 35467964 DOI: 10.1200/CCI.21.00173] [Reference Citation Analysis]
6 Rojas F, Hernandez S, Lazcano R, Laberiano-fernandez C, Parra ER. Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research. Front Oncol 2022;12:889886. [DOI: 10.3389/fonc.2022.889886] [Reference Citation Analysis]
7 Plana D, Fell G, Alexander BM, Palmer AC, Sorger PK. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nat Commun 2022;13:873. [PMID: 35169116 DOI: 10.1038/s41467-022-28410-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Woodford RG, Zhou DD, Kok PS, Lord SJ, Friedlander M, Marschner IC, Simes RJ, Lee CK. The validity of progression-free survival 2 as a surrogate trial end point for overall survival. Cancer 2022. [PMID: 34985773 DOI: 10.1002/cncr.34085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Chan KK, Tannock IF. Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers? J Clin Oncol 2021;39:2426-9. [PMID: 33979191 DOI: 10.1200/JCO.21.00552] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dehbi HM, Embleton-Thirsk A, McCaw ZR. Sample size calculation for randomized selection trials with a time-to-event endpoint and a margin of practical equivalence. Stat Med 2022. [PMID: 35688463 DOI: 10.1002/sim.9490] [Reference Citation Analysis]
11 Ascierto PA, Butterfield LH, Finn OJ, Futreal A, Hamid O, LaVallee T, Postow MA, Puzanov I, Sosman J, Fox BA, Hwu P. The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021. J Transl Med 2022;20:179. [PMID: 35449104 DOI: 10.1186/s12967-022-03384-w] [Reference Citation Analysis]